Dr. Muni joined CutisPharma as President in July 2014 and was named Chief Executive Officer in May 2015. Prior to joining CutisPharma, Dr. Muni served as the Executive Director of New Product Planning at Sunovion Pharmaceuticals, a US subsidiary of Sumitomo Dainippon Pharma, leading the Corporate Strategy group’s commercial assessment of the company’s R&D portfolio and corporate M&A and licensing activities.
Prior to joining Sunovion, Dr. Muni was an engagement manager in the strategic advisory practice of the healthcare investment bank Leerink Swann, LLC. Prior to that, Dr. Muni was a Medical Officer in the Division of Cardiovascular Devices at the FDA. Dr. Muni has maintained staff appointments with the Department of Medicine at Brigham and Women’s Hospital and Harvard Medical School for over 15 years, completing his residency at the Brigham and Women’s Hospital in Internal Medicine. He received his M.D. as well as Master of Science in Public Health, from the Tulane School of Medicine, and a B.A. in Business Economics and B.Sc. in Biochemistry from Brown University.